<html>
<head>
  <title>Neoantigen-directed immune escape in lung cancer evolution</title>
  <basefont face="微软雅黑" size="2" />
  <meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
  <meta name="exporter-version" content="YXBJ Windows/600753 (zh-CN, DDL); Windows/10.0.0 (Win64);"/>
  <style>
    body, td {
      font-family: 微软雅黑;
      font-size: 10pt;
    }
  </style>
</head>
<body>
<a name="939"/>
<h1>Neoantigen-directed immune escape in lung cancer evolution</h1>

<div>
<span><div style="text-align: center;"><span style="font-size: 18pt;"><span style="font-size: 18pt; font-family: &quot;Times New Roman&quot;;">Neoantigen-directed immune escape in lung cancer evolution</span></span></div><div><span style="min-height: 12pt;"><span style="font-size: 14pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;; font-weight: bold;">aims</span></span><span style="min-height: 12pt; font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;; font-weight: bold;">：</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                1）确认在未经治疗的非小细胞肺癌中存在异质性的情况。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                2）观察</span><span style="font-size: 14px; color: rgb(46, 48, 51); font-family: &quot;Times New Roman&quot;; font-variant-numeric: normal; line-height: 18px;">免疫浸润在肿瘤演化中的变化情况。</span></div><div><span style="font-size: 14px; color: rgb(46, 48, 51); font-family: &quot;Times New Roman&quot;; font-variant-numeric: normal; line-height: 18px;">              3）探索</span><span style="font-size: 14px; color: rgb(46, 48, 51); font-family: &quot;Times New Roman&quot;; font-variant-numeric: normal; line-height: 18px;">免疫逃避机制与临床结果的关系，为提高患者临床收益提供好的指导。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                4）调查转录本的表达是否是新抗原的损耗机制之一。</span></div><div><font style="font-size: 14pt;"><span style="font-size: 14pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">material</span><span style="font-size: 14pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">:</span></font></div><div><span style="min-height: 12pt; font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">            对88个早期未经治疗的非小细胞肺癌患者的258个组织进行RNA测序。</span></div><div><font style="font-size: 14pt;"><span style="font-size: 14pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">discussion and conclusion：</span></font></div><div><span style="font-family: &quot;Times New Roman&quot;;">            </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;"> 1）： </span><span style="font-size: 14px; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(46, 48, 51); font-family: &quot;Times New Roman&quot;; font-variant: normal; font-weight: bold; line-height: 18px;">免疫浸润异质性</span></div><div><span style="font-size: 14px; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; color: rgb(46, 48, 51); font-family: &quot;Times New Roman&quot;; font-variant: normal; line-height: 18px;">                 评估方法：</span><span style="min-height: 9pt; font-size: 7pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">根据gene的RNA表达来评估免疫浸润的程度，分为高免疫浸润和低免疫浸润。（方法依据：</span><span style="min-height: 9pt; font-size: 7pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes.</span><span style="min-height: 9pt; font-size: 7pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;; font-style: italic;">J. Immunother. Cancer</span> <span style="min-height: 9pt; font-size: 7pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;; font-weight: bold;">5</span><span style="min-height: 9pt; font-size: 7pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">, 18 (2017))</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                   总结： 1.1. 71%的患者 各组织免疫浸润性比较一致（low (38 tumours (43%)，high (25 tumours (28%)），</span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">29%的患者各组织中免疫浸润程度不一致。表明同一肿瘤患者不同组织间的确存在着免疫浸润异质性的情况。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                1.2 异质性高的肿瘤组织TMB呈现不一致的趋势；</span><span style="font-family: &quot;Times New Roman&quot;;">21%（12/57）高TMB 最少有一个低TMB组织区域。</span><span style="font-family: &quot;Times New Roman&quot;;">TMB分布不均肿瘤组织中，低TMB区域肿瘤纯度明显偏低。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                               </span> <span style="color: rgb(255, 0, 0); font-family: &quot;Times New Roman&quot;;">1.3  </span><span style="color: rgb(255, 0, 0); font-family: &quot;Times New Roman&quot;;">瘤内异质性干扰了对基因组和转录组中生物标志物的检测评估，</span><span style="color: rgb(255, 0, 0); font-family: &quot;Times New Roman&quot;;">在做TMB评估的时候应该考虑肿瘤的异质性问题。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">          </span> <span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;"> </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">2）：免疫浸润与肿瘤的进化</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                    评估方法：计算来自于同一肿瘤不同区域 基因组特征差异与免疫环境差异的关系.</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                          总结：2.1 基因组距离越大的肿瘤细胞，免疫微环境差异越大。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                      2.2 </span><span style="min-height: 12pt; font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">CD8</span><span style="min-height: 12pt; font-size: 6.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">+</span> <span style="min-height: 12pt; font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">T cell 免疫浸润程度越高的区域，</span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">子克隆多样性越低。</span></div><div><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">                                         2.3 免疫浸润低的区域</span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">子克隆区域多样性明显偏高。</span></div><div><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">    </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">     </span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">   </span><span style="font-family: &quot;Times New Roman&quot;;"> 2.4 </span><span style="font-size: 9pt; color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">肿瘤的演化形成与RNA表达水平的抗原呈递、DNA水平新生抗原的自我突变都有着密切的关系</span><span style="font-size: 9pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">            </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">3）：免疫编辑和免疫微环境</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                    评估方法：通过比较肿瘤中实际检测到的新抗原数量与预估数量的差异，小于1分认为存在DNA免疫编辑事件发生。（方法依据：Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. &amp; Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity.）</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                            总结：3.1 新生抗原定义：Neoantigens were defined as peptides with a predicted binding affinity &lt; 500 nM or a rank percentage score &lt; 2%;</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        3.2 强新生抗原定义：strong neoantigens were defined as those with a predicted binding affinity &lt; 50 nM or a rank percentage score &lt; 0.5%；</span></div><div style="min-height: 12pt; text-align: left;"><span style="min-height: 12pt; font-size: 9.5pt;"><span style="font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">                                         3.3 新发HLA类型越少，检查到的新生抗原越少。</span></span></div><div style="min-height: 12pt; text-align: left;"><span style="min-height: 12pt; font-size: 9.5pt;"><span style="font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">                                         3.4 低免疫浸润区域更容易观察到比预期要多的新抗原。</span></span></div><div style="min-height: 12pt; text-align: left;"><span style="min-height: 12pt; font-size: 9.5pt;"><span style="font-size: 9.5pt; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">                                         3.5 50% （43/88） 的肿瘤中至少有一个新抗原的丢失是因为子克隆发生了CNV事件。</span></span></div><div style="min-height: 12pt; text-align: left;"><span style="min-height: 12pt; font-family: &quot;Times New Roman&quot;;">                                       </span><span style="font-family: &quot;Times New Roman&quot;;"> 3.6 </span><span style="min-height: 12pt; font-size: 14px; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(247, 248, 250); color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;; font-variant: normal; line-height: 26px;">在浸润程度较低的肿瘤中，亚克隆的免疫编辑减少情况在没有新抗原拷贝数丢失证据的肿瘤中更为常见，暗示着CNV-loss也许是免疫编辑的分子机制。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">            </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">4）：新抗原转录本的抑制</span></div><div><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">    </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">    </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">    </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">  </span> <span style="font-family: &quot;Times New Roman&quot;;">     评估方法：通过甲基化测序，比较新抗原基因与非抗原基因启动子区甲基化程度。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                            总结：4.1 </span><span style="font-size: 12.6667px; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">仅有33%的抗原在转录后表达。</span></div><div><span style="font-size: 12.6667px;"><span style="font-size: 12.6667px; color: rgb(1, 1, 1); font-family: &quot;Times New Roman&quot;;">                                         4.2 高免疫浸润或者不均一免疫浸润区域的抗原表达明显落后。</span></span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        4.3 仅高免疫浸润、不均一免疫浸润区域 或者有着HLA完整分型的区域 存在新抗原的损耗现象， 这表明免疫浸润肿瘤的亚克隆中HLA-loss或新抗原表达抑制的发生都可能造成免疫逃逸。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        4.4 有抗原的区域，无表达基因相比于有表达基因，启动子区域的甲基化高达11.4倍；而无抗原区域则无明显差异；</span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">结果表明免疫逃逸很有可能与启动子甲基化导致的新抗原表达沉默有关。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        4.5  </span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">新抗原表观遗传上的表达抑制也许能为检查点抑制疗法中的耐药产生原理找到新的解释。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">            </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">5）：抗原呈递的干扰</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                            总结：5.1 </span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">HLA-loss 和突变影响着抗原呈递的过程，抗原呈递的功能紊乱是免疫逃逸重要的分子机制之一。 </span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        5.2 特别是HLA-C的丢失可能导致杀伤细胞免疫球蛋白样受体信号的丢失。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        5.3  HLA-C1,HLA-C2  对杀伤细胞免疫球蛋白样受体具有不同的特异性，</span><span style="font-family: &quot;Times New Roman&quot;;">来自纯合HLA-C等位基因患者的肿瘤细胞可能会逃避NK细胞的追杀。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                        5.5  HLA-C1和HLA-C2杂合区域自然杀伤细胞浸润程度较高。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                  </span> <span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">    </span> <span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">5.6 HLA-loss 会影响抗原信号的识别而影响肿瘤的的微环境。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">            </span><span style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">6）：免疫逃逸能力可作为愈后指标</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                              总结：6.1 肿瘤免疫能力划分：</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                   免疫逃逸能力低：</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                  1）</span><span style="font-family: &quot;Times New Roman&quot;;"> 全组织的高免疫浸润。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                  2） DNA免疫编辑打分 &gt;1分，即无免疫编辑事件发生。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                  3） 无抗原呈递的干扰。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                          6.2 免疫逃逸能力高：</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                 1）最少有一个区域是低免疫浸润区域 并且 抗原的呈递受到干扰</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                                 2）</span><span style="font-family: &quot;Times New Roman&quot;;">DNA免疫编辑打分 &lt;1分，即发生免疫编辑事件</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                         6.3 统计表明，低免疫逃逸能力者的患者无病生存期明显较长。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                         6.4 </span><span style="font-family: &quot;Times New Roman&quot;;">高新抗原负荷的肿瘤病人无病生存期明显较长，而亚克隆新抗原负荷或总新抗原负荷与无病生存无显著关系。</span><span style="font-family: &quot;Times New Roman&quot;;">在无免疫逃逸能力评估的情况下，新抗原负荷指标也可以有效的对评估肿瘤病人的免疫反应。</span></div><div><span style="font-family: &quot;Times New Roman&quot;;">                                       </span> <span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;"> 6.5  </span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">有着 高克隆新抗</span><span style="color: rgb(255, 0, 0); font-family: &quot;Times New Roman&quot;;">原负荷 或者 低免疫逃逸能力的肿瘤患者 无病生存期明显 提高。这种关系无论是从肿瘤分期、组织、年龄、性别、患病年限、参与辅助治疗等角度来看，都有着明显的相关性。</span><span style="font-family: &quot;Times New Roman&quot;;"> </span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">因此，</span><span style="color: rgb(255, 0, 0); font-family: &quot;Times New Roman&quot;;">新抗原负荷和</span><span style="color: rgb(227, 0, 0); font-family: &quot;Times New Roman&quot;;">免疫逃逸能力的大小都可以作为有效的指标来预测临床免疫收益。</span></div><div><br/></div></span>
</div></body></html> 